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The field of vascular molecular imaging is searching for the ‘‘holy grail’’ of an imaging technique that will
quantitatively and reliably assess vulnerable coronary plaques. Fluorescence imaging with indocyanine
green specifically identifies lipid-rich plaques in rabbits and in humans and represents a promising, though
invasive, approach.Myocardial infarction (MI), a consequence
of coronary atherosclerosis, remains the
leading cause of death in the Western
world despite advances in risk factor
identification and modification (Lloyd-
Jones et al., 2010). However, the develop-
ment of novel therapies designed to
prevent MI has stalled, with several large
pharmaceutical companies declaring
themselves out of the business. There is
no dearth of potential novel targets, but
one of the major reasons for reluctance
is the very high cost of cardiovascular
outcome trials and the daunting challenge
of early proof of concept, that is, the ability
to reliably demonstrate that a novel
therapy has effects on atherosclerotic
plaques that would be expected to
reduce MI if advanced into a large
outcome trial.
MI occurs as the result of rupture of
a ‘‘vulnerable’’ coronary atherosclerotic
plaque, which is often characterized by
a large, lipid-rich core and increased
inflammatory activity (Virmani et al.,
2006). Current approaches to atheroscle-
rosis imaging do not adequately differen-
tiate between inflammatory lipid-rich pla-
ques and stable lipid-poor plaques
(Figure 1)—particularly in the coronary
arteries—and therefore are not ideal for
use in assessing novel therapeutic ap-
proaches. The field is still looking for a
‘‘holy grail’’ of an imaging technique that
will reliably assess inflammatory lipid-
rich plaques in the coronary arteries,
thus permitting the relatively short-term
assessment of novel therapeutic ap-
proaches targeted to this type of vulner-
able plaque. An FDA-approved product
currently in clinical use for retinal and
choroidal imaging using optical imagingis indocyanine green (ICG), and Vinegoni
and colleagues recently reported in
Science Translational Medicine (Vinegoni
et al., 2011) that near-infrared fluores-
cence (NIRF) coupled to the use of ICG
as an imaging agent specifically identified
lipid-rich plaques in vivo in a rabbit model
of atherosclerosis and, preliminarily,
ex vivo in human atherosclerotic lesions.
Nuclear and optical imaging methods
are the cornerstone of in vivo vascular
molecular imaging because of their high
detection sensitivity (Vancraeynest et al.,
2011). Positron emission tomography
(PET) has been used for noninvasive
detection of atherosclerosis. When used
with [18F]fluorodeoxyglucose (18FDG), a
tracer that is taken up by macrophages
within the atherosclerotic plaque (Ogawa
et al., 2004), FDG PET combined with
computed tomography (CT) permits the
imaging of plaque ‘‘activity.’’ Further-
more, 18FDG PET/CT vascular imaging
has been shown in humans to be modu-
lated by cholesterol lowering with statin
drugs (Tahara et al., 2006) and also poten-
tially prognostic of future vascular events
in a retrospective study (Rominger et al.,
2009). However, current studies have
assessed only aortic or carotid plaques,
and one of the major drawbacks of
18FDG PET/CT is the inability to image
coronary artery plaques due to spatial
resolution limitations.
Optical molecular imaging using NIRF
imaging has been widely used in preclin-
ical studies of atherosclerosis (Calfon
et al., 2010). Optical imaging by NIRF
can furnish images of cellular processes
(Wunder and Klohs, 2008) such as aug-
mented protease activity (Jaffer et al.,
2008), observed in atherosclerosis atCell Metaboshallow depths, and (1) has exceptional
spatial resolution with high sensitivity; (2)
uses nonionizing radiation; (3) accommo-
dates a broad array of attachment chem-
istries; and (4) accommodates a wide
array of detection systems, including
catheters capable of accessing human
coronary arteries. In the interest of using
NIRF to detect vulnerable plaques, Vine-
goni et al. (Vinegoni et al., 2011) recog-
nized that ICG is a lipophilic molecule
that accumulates at sites of lipid and
inflammation. After intravenous injection
in rabbits, they showed that ICG colocal-
ized with neutral lipid in aortic plaque
and localized to atheroma, confirmed
by intravascular ultrasound and an-
giography. Furthermore, in freshly re-
sected human carotid endarterectomy
specimens incubated with ICG, NIRF
microscopy and correlative histology
demonstrated that ICG colocalized with
lipid-rich atheroma and macrophages,
but not with collagen. Together, these
results suggested that ICG may be useful
as a NIRF-based imaging agent specifi-
cally for inflammatory, lipid-rich athero-
sclerotic plaques.
Despite these provocative findings, will
NIRF with ICG be valid for detecting
lipid-rich coronary plaques in humans,
and more importantly, will it permit the
short-term assessment of novel thera-
peutic approaches targeted to the lipid-
rich vulnerable plaque in humans? ICG is
FDA approved; therefore, safety and
tracer dynamics in vivo are already com-
pleted for studies of the liver and the
retina. In settings such as coronary
imaging, where low background images
need to be acquired quickly, ICG is favor-
able because it is rapidly cleared fromlism 14, July 6, 2011 ª2011 Elsevier Inc. 7
Figure 1. Anatomy of Coronary Plaques
The plaque on top has a large, lipid-rich core and active inflammation and
would be considered ‘‘vulnerable.’’ The plaque on the bottom is rich in vascular
smooth muscle cells and extracellular matrix, has much less lipid and active
inflammation, and would be considered ‘‘stable.’’ Both plaques obstruct the
lumen to a similar extent, but the former would be much more likely to cause
MI. Standard coronary angiography and even intravascular ultrasound do
not reliably differentiate between these types of plaque. On the other hand,
near-infrared fluorescence imaging with indocyanine green as an imaging
agent might be expected to readily differentiate between the two.
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an animal model demon-
strating that catheter-based
approaches may reliably
image ICG to identify lipid-
rich plaques (Vinegoni et al.,
2011), rapid translation into
human use is the next logical
step. Future studies will
need to focus on optimizing
human catheter develop-
ment, determining precise in-
jection and imaging time
points, and performing con-
firmatory studies with more
established technologies
such as intravascular ultra-
sound. Validation will require
demonstration that plaques
identified by this approach
are responsive to therapies—
such as statins—known to
impact on lipid-rich plaques.
Even then, there will remain
the daunting task of proving
that plaques imaged using
this approach are actually
more ‘‘vulnerable’’ as de-
fined by hard cardiovascular
outcomes.
An important limitation of
this approach is the require-
ment for direct catheter
imaging and thus the invasive
nature of the technology,
which limits the approach to
individuals with a clinical
indication for coronary angiog-
raphy and, for investigation of
new therapies, would require
two invasive procedures. An
interest in circumventing the
need for a vascular invasive
approach leads to the fol-
lowing questions: (1) Can use
of endoscopic (i.e., esopha-
geal) techniques provide an
alternative to direct coronary
access as an imaging ap-proach for NIRF-based detectors? (2) Can
the scatter of NIRF signals be magnified or
better detected by software improvement
to potentially allow for noninvasive detec-
tion? (3) Can atheroma within human coro-
nary arteries ever be resolved noninvasively8 Cell Metabolism 14, July 6, 2011 ª2011 Elswith the high fidelity of invasive catheter-
based techniques? In addition to these
questions specific to NIRF, the field needs
a better understanding about which of the
plaque characteristics—biological, molec-
ular, and morphological—predict variousevier Inc.outcomes of interest (i.e.,
reduction of plaque size, lipid
content, inflammatory proper-
ties, and/or cardiovascular
events) before these tech-
niques are applied in clinical
use. Despite the clear chal-
lenges, it will be interesting to
see whether fluorescent green
will bring us closer to reliable
imaging of the vulnerable
plaque.REFERENCES
Calfon, M.A., Vinegoni, C., Ntziach-
ristos, V., and Jaffer, F.A. (2010).
J. Biomed. Opt. 15, 011107.
Jaffer, F.A., Vinegoni, C., John,
M.C., Aikawa, E., Gold, H.K., Finn,
A.V., Ntziachristos, V., Libby, P.,
and Weissleder, R. (2008). Circula-
tion 118, 1802–1809.
Lloyd-Jones, D., Adams, R.J.,
Brown, T.M., Carnethon, M., Dai,
S., De Simone, G., Ferguson, T.B.,
Ford, E., Furie, K., Gillespie, C.,
et al; WRITING GROUP MEMBERS;
American Heart Association Statis-
tics Committee and Stroke Statistics
Subcommittee. (2010). Circulation
121, e46–e215.
Ogawa, M., Ishino, S., Mukai, T.,
Asano, D., Teramoto, N., Watabe,
H., Kudomi, N., Shiomi, M., Magata,
Y., Iida, H., and Saji, H. (2004).
J. Nucl. Med. 45, 1245–1250.
Rominger, A., Saam, T., Wolpers, S.,
Cyran, C.C., Schmidt, M., Foerster,
S., Nikolaou, K., Reiser, M.F., Bar-
tenstein, P., and Hacker, M. (2009).
J. Nucl. Med. 50, 1611–1620.
Tahara, N., Kai, H., Ishibashi, M.,
Nakaura, H., Kaida, H., Baba, K.,
Hayabuchi, N., and Imaizumi, T.
(2006). J. Am. Coll. Cardiol. 48,
1825–1831.
Vancraeynest, D., Pasquet, A., Roe-
lants, V., Gerber, B.L., and Vanover-
schelde, J.L. (2011). J. Am. Coll.
Cardiol. 57, 1961–1979.
Vinegoni, C., Botnaru, I., Aikawa, E.,
Calfon, M.A., Iwamoto, Y., Folco,
E.J., Ntziachristos, V., Weissleder,R., Libby, P., and Jaffer, F.A. (2011). Sci. Transl.
Med. 3, 84ra45.
Virmani, R., Burke, A.P., Farb, A., and Kolodgie,
F.D. (2006). J. Am. Coll. Cardiol. 47 (8, Suppl),
C13–C18.
Wunder, A., and Klohs, J. (2008). Basic Res. Car-
diol. 103, 182–190.
